Clinical Trial Update: Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial is evaluating enfortumab vedotin in combination with stereotactic radiation for localized, cisplatin-ineligible muscle-invasive bladder cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Muscle-invasive Bladder Cancer

Drugs mentioned

• Enfortumab Vedotin (enfortumab vedotin)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Bladder Cancer | Phase 1, Phase 2 | Status: RECRUITING